CB8025 21629 Primary Biliary Cholangitis: An 8‐week, dose ranging, open label, randomized, Phase 2 study with an 18‐week extension, to evaluate the safety and efficacy of MBX‐8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA).

February 08, 2017
Gastroenterology - Stomach
Principal Investigator: Stuart C Gordon, MD

The purpose of this research study is to compare the effectiveness and safety of MBX‐8025 on Primary Biliary Cholangitis (PBC) when available treatment with UDCA has proved inadequate or not tolerated.

Confirmed diagnosis of Primary Biliary Cholangitis.  Please contact us for further information.